TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05051072

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia
Description: Assessment of the trigeminal nerve by diffusion tensor MRI and in resting state in the context of essential neuralgia
Study: NCT06080087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-TEAM
Description: I-TEAM is a web-based implementation toolkit that supports to enhance cultural responsiveness of EI providers in their EBP delivery with minoritized families of young autistic children
Study: NCT04772651

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation on depression
Description: Psychoeducation on depression (50minutes once a week for 4 weeks)
Study: NCT05608824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear wave elastography and microvascular flow imaging.
Description: Subjects will undergo serial SWE and MFI imaging throughout their rehabilitation episode of care to assess changes over time, status in rehabilitation and comparison to the contralateral extremity.
Study: NCT05248100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer
Description: The intervention is a one-time cash transfer of 22,500 Tanzanian Shillings (\~$10), with half (11,250 TSH) delivered upon enrollment in the study and half delivered after confirmation of the completion of a clinical visit if within 90 days of study enrollment.
Study: NCT05962099

Intervention type: BEHAVIORAL
Intervention: Lifestyle and weight loss advice
Description: Commercially available lifestyle and weight loss intervention
Study: NCT05798702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: roux -en-y- gastric bypass
Description: Roux-\&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: intensive life style modification
Description: Weight loss will be induced using a VLCD (800-850 kcal/day; 59% carbohydrate, 13% fat, 26% protein, 2% fiber) with replacement meals for 2 months, followed by structured food reintroduction every 2-8 weeks (about 50% carbohydrate, 35% total fat, and 15% protein), and an ongoing structured program with follow-up visits up to 25% body weight loss
Study: NCT05465785

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 vaccine (Sf9 cell)
Description: This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (Sf9 cell)
Description: This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified
Study: NCT05143294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conectar Jugando Classroom Program
Description: Modern Board Games Intervention in Elementary Classrooms
Study: NCT06275841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vepdegestrant
Description: experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Experimental treatment to assess an endpoint
Study: NCT05185973

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: For Baby supplements provided as powder
Description: One sachet daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Micronutrient powder provided as powder
Description: One sachet daily
Study: NCT06249906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercial bone implant product Group
Description: Commercial bone implant product Group with a smooth surface （without particular microstructures）.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirco-structured Bioceramic Group
Description: β-tri-Calcium phosphate with microstructures such as grooves, patterns and so on.
Study: NCT05500326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Tablets
Description: ITCHY Study:~All participants will receive one dose of oral ivermectin 3mg on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~ITCHY2 Study:~Participants will receive one age-specific dose of oral ivermectin on day 0 and have two blood samples taken to determine the serum ivermectin concentrations after the dose. Timing of blood samples will vary depending on the allocated group.~Age specific ivermectin dose:~* 0.75mg of ivermectin will be given to participants aged 3 to 7 months~* 1.5mg of ivermectin will be given to participants aged 8 to 12 months~* 3mg of ivermectin will be given to participants aged 13 to 24 months
Study: NCT05207163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuing medical education
Description: Education section about knowledge of transmissions, severity of viral hepatitis B-C and update treatment strategy of the HBV-HCV
Study: NCT06550544

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office hysteroscopy
Description: A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. Vaginoscopic approach will be used. A 5 F grasper will be used to grasp and extract the IUD.~Pain intensity will be assessed by visual analogue scale immediately after the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided
Description: An alligator forceps will be introduced into the uterine cavity under ultrasound sound guidance. The IUD will be grasped and extracted outside the uterus.~Pain intensity will be assessed by visual analogue scale immediately after the procedure.
Study: NCT05632783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin Sulfate Sodium
Description: Chondroitin sulfate 800 mg tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT06335953

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led deprescribing intervention
Description: The intervention consists of the following strategies: 1) Pharmacists will participate in a 20-minute webinar and receive a laminated tip sheet about the study; 2) Eligible patients and their care partners will receive a single deprescribing educational brochure by mail; 3) Patients and their care partners will have a single telemedicine visit in which the pharmacist will perform medication reconciliation and identify potential adverse effects and concerns related to medicines; 4) The pharmacist will send the PCP up to 3 deprescribing recommendations in the EHR using a standardized template; 5) With the PCP's approval, the pharmacist will call the patient or care partner to implement the deprescribing recommendations and document changes in the EHR.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-led deprescribing intervention
Description: The intervention consists of the following strategies: 1) Pharmacists will participate in a 20-minute webinar and receive a laminated tip sheet about the study; 2) Eligible patients and their care partners will receive a single deprescribing educational brochure by mail; 3) Patients and their care partners will have a single telemedicine visit in which the pharmacist will perform medication reconciliation and identify potential adverse effects and concerns related to medicines; 4) The pharmacist will send the PCP up to 3 deprescribing recommendations in the EHR using a standardized template; 5) With the PCP's approval, the pharmacist will call the patient or care partner to implement the deprescribing recommendations and document changes in the EHR.
Study: NCT06583291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic dopaminergic neural precursor cell(iDAP)
Description: Bilateral implantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic dopaminergic neural precursor cell(iDAP)
Description: Bilateral implantation
Study: NCT05781321

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Hypofractionated Radiation Therapy
Description: Undergo short course RT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT simulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT simulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorodopa F 18
Description: Given IV
Study: NCT04709185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 MG Oral Tablet
Description: oral 1 mg dexamethasone at 23:00-24:00 the night before AVS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo at 23:00-24:00 the night before AVS
Study: NCT06252454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Furosemide will be used to block C fibers in the lungs, thus lowering intensity of sensation of dyspnea.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodropropizine
Description: Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodropropizine
Description: Levodropropizine will be used to block C fibers in the airways, to evaluate if this double block of C fibers will have any effect on lowering intensity of dyspnea sensation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - saline
Description: Placebo will be used as a comparator
Study: NCT05389202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perfusion CT scanning
Description: Abdominopelvic CT scan with perfusion and spectral analysis performed 7 days (± 5 days) before prostate embolization.
Study: NCT05781321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorodopa F 18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04749329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh Group
Description: All MG patients underwent the procedure with ante rectus positioned prophylactic mesh according to the following standardized technique. A BIO-A circular-shaped mesh measuring 8X10 cm in diameter is prepared with an internal 2 cm hole to let the bowel pass.~An at least 8x8 cm space is created between the anterior rectus sheath and the rectus abdominis muscle and, then, the mesh is positioned. The bowel is passed through the rectus muscle via the circular incision in the middle of the mesh. Single absorbable monofilament sutures anchored the mesh laterally in the ante rectus pocket, while medially the mesh is fixed with four stitches to the colon and to both the anterior rectal sheet. The stoma is attached to the skin similarly to CG patients.
Study: NCT04919369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study: NCT05781321

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06432361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource Allocation
Description: Those in the intervention condition will receive weekly personalized information summarizing the previous week's resource allocation (e.g., personalized information on how they spent their time and money) in relation to their personal goals, interests, and alcohol use. They will also see a summary of how they spent their time and money in relation to their set goals for the week The information in the intervention feedback will be obtained from participant's responses to the daily surveys on how they spent their time and money each day. Reviewing the intervention feedback should take no longer than 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment only control
Description: participants will complete a 3 week monitoring period of daily surveys assessing time spent in various domains during the time, alcohol use, personal goals, and money spent on alcohol and substance-free activities. Each daily survey should take no longer than 5 minutes to complete.
Study: NCT05781321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard course RT
Study: NCT06551337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.
Study: NCT05461326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quad tendon
Description: quadriceps tendon autograft
Study: NCT05781321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04919369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Given PO
Study: NCT05881213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378 (low-dose)
Description: Quaque day (QD), PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-378 (low-dose)
Description: Quaque day (QD), PO
Study: NCT01302106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine plus low dose Ara-C
Description: Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
Study: NCT04552015

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TST vs PPD microneedle test
Description: TST vs First patch: 800 um in length, PPD1 formulation; Second patch: 1,500 um in length, PPD1 formulation; Third patch: 800 um in length, PPD2 formulation; and Fourth patch: 1,500 um in length, PPD2 formulation
Study: NCT05521256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-6856
Description: Participants will receive NN0113-6856 orally or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0113-6856
Description: Participants will receive NN0113-6856 orally or intravenously.
Study: NCT05461326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BTB
Description: patellar tendon autograft
Study: NCT05283564

Intervention type: OTHER
Group type: OTHER
Intervention: Percussive Ventilation Breathhold SABR (PVB-SABR)
Description: Number of lung cancer patients with successful administration of PVB technique in PVB-SABR treatment
Study: NCT05521256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo of NNC0113-6856 for each of the oral cohorts.
Study: NCT06037044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory integration therapy for balance and gait training
Description: Sensory integartion Walking pathway with obstacles x10 rep, standing on one leg with eyes op5-10 sec x10 rep)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensory integration therapy for balance and gait training
Description: Sensory integartion Walking pathway with obstacles x10 rep, standing on one leg with eyes op5-10 sec x10 rep)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physiotherapy for balance and gait training
Description: Traditional Physiotherapy walking pathway with obstacles x10 rep, standing on one leg with eyes open 5-10 sec x10 rep

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy for balance and gait training
Description: Traditional Physiotherapy walking pathway with obstacles x10 rep, standing on one leg with eyes open 5-10 sec x10 rep
Study: NCT06413459

Intervention type: OTHER
Intervention: Luminex; scRNAsec
Description: Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses

Intervention type: OTHER
Intervention: Luminex; scRNAsec
Description: Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses

Intervention type: OTHER
Intervention: Luminex; scRNAsec
Description: Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses

Intervention type: OTHER
Intervention: Luminex; scRNAsec
Description: Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses
Study: NCT04970459

Intervention type: BIOLOGICAL
Intervention: collection of samples of blood and urine
Description: extra samples of blood and urine will be collected and stored for research utilisation
Study: NCT06507475

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
Study: NCT06438835

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PneuFlex AFO Assist
Description: It features a pneumatic artificial muscle designed to enhance ankle foot orthosis functionally for patients with mobility issues.
Study: NCT05821335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leap motion assisted rehabilitation
Description: Hand Therapy via leap motion sensor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional program
Description: Hand Therapy by physiotherapist via traditional methods
Study: NCT05362474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 10mg orally once a day
Study: NCT05027984

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: OCT images will be acquired by means of the FD C7 XR system or the OPTIS system (both St. Jude Medical, St. Paul, MN, USA) with a non-occlusive technique.(33) The acquired OCT coronary images will be analyzed on-line using a proprietary OCT console (St Jude Medical, Inc., USA). Definitions and cut-offs for OCT vulnerability parameters derived from available consensus documents and from main IVUS/OCT studies.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iFR/FFR/RFR
Description: The iFR and FFR measurements will be obtained using a coronary-pressure guidewire (Pressure Wire / Certus or Aeris for FFR assessment and PressureWire™ X Guidewire/QUANTIEM™ for the RFR assessment by Abbott Vascular, Abbott Park, Illinois, U.S.A; Comet by Boston Scientific, Marlborough, MA, USA), OptoWire by Opsens, Quebec, Canada, or Verrata by Philips, San Diego, CA, USA.).
Study: NCT06266104

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Image Enhanced Endoscopy Filters
Description: Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Image Enhanced Endoscopy Filters
Description: Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Image Enhanced Endoscopy Filters
Description: Patients that undergoing surveillance and consent to be involved in the study will be randomised to undergo surveillance with LCI, TXI or dye-spray chromoendoscopy (methylene blue).